Tofogliflozin decreases body fat mass and improves peripheral insulin resistance

Diabetes, Obesity and Metabolism - Tập 20 Số 5 - Trang 1311-1315 - 2018
Ren Matsuba1, Ikuro Matsuba2, Mototsugu Shimokawa3, Yoshio Nagai1, Yasushi Tanaka1
1Department of Internal Medicine, Division of Metabolism and Endocrinology St Marianna University School of Medicine Kanagawa Japan
2Matsuba Medical Clinic Kanagawa Japan
3Department of Cancer Information Research, National Kyushu Cancer Center, Clinical Research Institute, Fukuoka, Japan

Tóm tắt

The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared between before and after tofogliflozin administration for 12 weeks in 16 patients with T2DM who were receiving dipeptidyl peptidase‐4 inhibitor treatment: body weight (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body composition. Peripheral glucose uptake (M value and M/I ratio) was examined by the hyperinsulinaemic‐euglycaemic clamp method. After 12 weeks, there was a significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). The change in the M value after 12 weeks of tofogliflozin therapy was correlated with the change in body fat mass (P < .05). Tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake in patients with T2DM. These improvements were significantly correlated with reduction in body fat mass.

Từ khóa


Tài liệu tham khảo

10.1038/nutd.2014.20

10.1007/s40265-017-0697-1

10.1111/dom.12898

10.1111/dom.12451

10.1172/JCI70704

10.1152/ajpendo.1979.237.3.E214

10.1007/978-4-431-55720-3_15

10.1016/j.cmet.2017.04.011

10.1038/srep32887

Seino Y, 2017, Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52‐week, open‐label, single‐arm study, J Diabetes Investig

10.1210/en.2015-1588

10.1210/jc.2006-1882

10.1210/en.2008-1137

10.1111/dom.12838

10.2337/dcS15-3005

10.1186/s12933-016-0440-3

10.1056/NEJMoa1504720

Thông tin
Thông tin xuất bản

Diabetes, Obesity and Metabolism

Tập 20 Số 5

1311-1315

Thông tin tác giả